These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25016628)

  • 21. Obinutuzumab: first global approval.
    Cameron F; McCormack PL
    Drugs; 2014 Jan; 74(1):147-54. PubMed ID: 24338113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic Leukemia.
    Korman AM; Hastings JG; Byrd JC; Kaffenberger BH
    JAMA Dermatol; 2017 Jan; 153(1):108-110. PubMed ID: 27892987
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA approves breakthrough immunotherapy for patients with non-small-cell lung cancer.
    Printz C
    Cancer; 2017 Jan; 123(2):191. PubMed ID: 28067949
    [No Abstract]   [Full Text] [Related]  

  • 24. Seamless Oncology-Drug Development.
    Prowell TM; Theoret MR; Pazdur R
    N Engl J Med; 2016 May; 374(21):2001-3. PubMed ID: 27074059
    [No Abstract]   [Full Text] [Related]  

  • 25. Alemtuzumab and myelodysplasia: a story of love and hate (possible alemtuzumab-induced myelodysplastic changes).
    Braester A; Akria L; Suriu C; Sonkin V
    Acta Haematol; 2013; 129(3):185-6. PubMed ID: 23257842
    [No Abstract]   [Full Text] [Related]  

  • 26. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia.
    Pitini V; Cascio A; Arrigo C; Altavilla G
    Br J Haematol; 2012 Jan; 156(1):1. PubMed ID: 21790529
    [No Abstract]   [Full Text] [Related]  

  • 27. NCCN: New directions in chronic lymphocytic leukemia.
    O'Brien S
    Cancer Control; 2001; 8(6 Suppl 2):114-7. PubMed ID: 11760553
    [No Abstract]   [Full Text] [Related]  

  • 28. Invasive fungal infections after obinutuzumab monotherapy for refractory chronic lymphocytic leukemia.
    Tse E; Leung RY; Kwong YL
    Ann Hematol; 2015 Jan; 94(1):165-7. PubMed ID: 24879095
    [No Abstract]   [Full Text] [Related]  

  • 29. Programmed death protein 1 inhibitors making inroads in multiple cancers.
    Brower V
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
    [No Abstract]   [Full Text] [Related]  

  • 30. Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia.
    Gay ND; Kozin E; Okada C; Danilov AV; Spurgeon S
    Leuk Lymphoma; 2018 Sep; 59(9):2258-2260. PubMed ID: 29249186
    [No Abstract]   [Full Text] [Related]  

  • 31. [A new therapeutic alternative in chronic B-lymphocytic leukemia].
    Portal E
    Rev Infirm; 2002 Dec; (86):38-40. PubMed ID: 12630232
    [No Abstract]   [Full Text] [Related]  

  • 32. Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.
    Laurenti L; Tarnani M; Innocenti I; Savino G; Battendieri R; Larocca LM; Chiusolo P; Sorà F; Sica S; Efremov D; Leone G
    J Clin Oncol; 2008 Nov; 26(32):5299-301. PubMed ID: 18854557
    [No Abstract]   [Full Text] [Related]  

  • 33. Monoclonal antibodies: magic bullets with a hefty price tag.
    Shaughnessy AF
    BMJ; 2012 Dec; 345():e8346. PubMed ID: 23236036
    [No Abstract]   [Full Text] [Related]  

  • 34. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
    Byrd JC; Rai KR
    Semin Oncol; 2000 Aug; 27(4):xii-xv; discussion xv-xvi. PubMed ID: 10950363
    [No Abstract]   [Full Text] [Related]  

  • 35. Preclinical data expected for nucleotide GS 9219.
    AIDS Patient Care STDS; 2007 Apr; 21(4):289-90. PubMed ID: 17506142
    [No Abstract]   [Full Text] [Related]  

  • 36. Alemtuzumab in chronic lymphocytic leukemia.
    James DF; Kipps TJ
    Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disseminated cryptococcosis, invasive aspergillosis, and mucormycosis in a patient treated with alemtuzumab for chronic lymphocytic leukaemia.
    Henn A; Mellon G; Benoît H; Roos-Weil D; Jauréguiberry S; Mordant P; Fekkar A; Caumes E
    Scand J Infect Dis; 2014 Mar; 46(3):231-4. PubMed ID: 24450842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibodies in chronic lymphocytic leukemia.
    Ferrajoli A; Faderl S; Keating MJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1231-8. PubMed ID: 17020457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment and management of chronic lymphocytic leukemia in the elderly: what the pharmacist clinician should know.
    Johnson TM
    Consult Pharm; 2012 Apr; 27(4):274-85. PubMed ID: 22498987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
    Grey M
    Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.